Prof. Yuqin Song 宋玉琴
Chief Physician, Professor
Department of Lymphoma, Peking University Cancer Hospital, Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Standardized diagnosis and comprehensive treatment of lymphoma.
Dr. Song is Deputy Director of the Department of Lymphoma and Vice President of Peking University Cancer Hospital. Dr. Song earned a medical doctorate in clinical hematology in 1998, completed postdoctoral research at Peking University Health Science Center (2004–2006), and trained in lymphoma care in the US (2009–2010). Dr. Song has worked in the hospital’s Department of Lymphoma since 2006.
Professional roles
- Vice Chair, Lymphoid and Hematologic Oncology Committee, Chinese Society of Clinical Oncology for the Elderly
- Member, Lymphoma Committee, China Anti-Cancer Association
- Vice Chair, Youth Committee, Lymphoma Committee, China Anti-Cancer Association
- Member, Chinese Alliance Against Lymphoma
Name order: in Chinese the family name comes first (Song Yuqin). Papers usually list the name as Yuqin Song or Song Y.
Selected publications
264 papers on PubMed matched by name and affiliation; 45 as first or senior author since 2016. Most recent first- or senior-author papers:
- Hematol Oncol, 2026 (senior author): Peripheral CD4(+) T-Cell Reserve as a Potential Biomarker of CD20 × CD3 Bispecific Antibody Outcomes and BTK Inhibitor-Associated Immune Modulation in B-Cell Lymphoma. PubMed 42858312
- Am J Hematol, 2026 (first author): Current Treatment Landscape and Advances in Lymphoma in China: A Special Issue. PubMed 42596616
- Am J Hematol, 2026 (senior author): Upfront Autologous Stem Cell Transplantation in First Complete Remission for Advanced-Stage Extra-Nodal NK/T-Cell Lymphoma: A Multicenter Retrospective Study. PubMed 42475115
- Chin J Cancer Res, 2026 (senior author): Updates of CSCO guidelines for diagnosis and treatment of lymphoma: 2026 edition. PubMed 42421897
- Leuk Lymphoma, 2026 (senior author): Tailored approaches in mantle cell lymphoma: refining treatment paradigms with an expert panel opinion. PubMed 41841007
- Blood Adv, 2026 (senior author): Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed/refractory mantle cell lymphoma in Chinese adults. PubMed 40811825
- Cancers (Basel), 2026 (senior author): Clinical Characteristics and Prognosis of Primary Central Nervous System Lymphoma: A Retrospective Analysis. PubMed 41682011
- Ann Hematol, 2026 (senior author): Global, regional, and national patterns of change in the burden of Hodgkin lymphoma from 1990 to 2021: an analysis of the global burden of disease study 2021 and projections to 2035. PubMed 41591457
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion